-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298

Benzinga·11/05/2026 15:53:40
Listen to the news
Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $275 to $298.